Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas

被引:65
作者
Beauvillain, C
Mahe, M
Bourdin, S
Peuvrel, P
Bergerot, P
Riviere, A
Vignoud, J
Deraucourt, D
Wesoluch, M
机构
[1] CTR RENE GAUDUCHEAU,DEPT MED ONCOL & RADIOTHERAPY,F-44035 NANTES,FRANCE
[2] CHU NANTES,DEPT HEAD & NECK SURG,NANTES,FRANCE
[3] DEPT RADIOTHERAPY,ST NAZAIRE,FRANCE
[4] CTR FRANCOIS BACLESSE,DEPT MED ONCOL & RADIOTHERAPY,F-14021 CAEN,FRANCE
关键词
D O I
10.1097/00005537-199705000-00017
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
After neoadjuvant chemotherapy, a routine conservative approach followed by salvage surgery was evaluated in terms of local control and survival in cases of advanced potentially resectable hypopharyngeal carcinoma. Between 1985 and 1989, 92 patients with T3 or T4-N0,N3 operable squamous cell hypopharyngeal carcinomas received three courses of neoadjuvant chemotherapy every 2 weeks involving a combination of cisplatin, 100 mg/m(2), on day 1 and fluorouracil, 1 g/m(2), on days 2 to 5, followed by total laryngopharyngectomy plus postoperative radiotherapy in 47 patients (arm A) or radiotherapy alone in 45 patients (arm B). Randomization was always performed prior to chemotherapy. The response rates of turner and node to chemotherapy were, respectively, 67% in arm A versus 79% in arm B (P > 0.05) and 54% in arm A versus 73% in arm B (P > 0.05). Grade III or IV toxicity was similar, affecting 15% of patients and 7% of cycles in rum A versus 16% of patients and 6% of cycles in arm B, After a mean follow-up of 92 months, survival was statistically better (P = 0.04) in arm A (5-year overall survival, 37%; median survival, 40 months) than in arm B (19% and 20 months) because of a better local control rate (63% versus 39%; P < 0.01). Better results were obtained for mutilant surgery in terms of local control and overall survival, regardless of response to neoadjuvant chemotherapy.
引用
收藏
页码:648 / 653
页数:6
相关论文
共 15 条
[1]  
*DEP VET AFF LAR C, 1991, NEW ENGL J MED, V324, P1685
[2]  
DEPOOTER CMJ, 1991, CANCER RES, V51, P4523
[3]   OVERVIEW OF COMBINED MODALITY THERAPIES FOR HEAD AND NECK-CANCER [J].
DIMERY, IW ;
HONG, WK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (02) :95-111
[4]  
ENSLEY JF, 1984, CANCER, V54, P811, DOI 10.1002/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO
[5]  
2-E
[6]   EFFICACY OF ADJUVANT CHEMOTHERAPY FOR PATIENTS WITH RESECTABLE HEAD AND NECK-CANCER - A SUBSET ANALYSIS OF THE HEAD AND NECK CONTRACTS PROGRAM [J].
JACOBS, C ;
MAKUCH, R .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) :838-847
[7]   METASTATIC PATTERNS IN SQUAMOUS-CELL CANCER OF THE HEAD AND NECK [J].
KOTWALL, C ;
SAKO, K ;
RAZACK, MS ;
RAO, U ;
BAKAMJIAN, V ;
SHEDD, DP .
AMERICAN JOURNAL OF SURGERY, 1987, 154 (04) :439-442
[8]   ADJUVANT CHEMOTHERAPY FOR RESECTABLE SQUAMOUS-CELL CARCINOMAS OF THE HEAD AND NECK - REPORT ON INTERGROUP STUDY-0034 [J].
LARAMORE, GE ;
SCOTT, CB ;
ALSARRAF, M ;
HASELOW, RE ;
ERVIN, TJ ;
WHEELER, R ;
JACOBS, JR ;
SCHULLER, DE ;
GAHBAUER, RA ;
SCHWADE, JG ;
CAMPBELL, BH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (04) :705-713
[9]  
LEFEBVRE JL, 1994, P AN M AM SOC CLIN, V13, P283
[10]  
Million RRC., 1984, MANAGEMENT HEAD NECK, P373